Report: Abreu-to-Indians only has “50-50” chance

9 Comments

CBS Sports’ Jon Heyman reports that the Indians and Angels are close to finalizing a trade involving veteran outfielder and DH Bobby Abreu.

No word yet on what the Angels would receive in return, but it’s probably not going to be much.

Abreu, 38, hit just .253/.353/.365 with eight home runs across 585 plate appearances last season for Anaheim and no longer possesses much defensive range. He’s also owed a $9 million salary in 2012, which the Angels will likely have to eat all or most of.

Abreu will presumably start in left field this year for Cleveland if the trade indeed goes down. Which has us wondering whether he’s really any better than Shelley Duncan, all things considered.

UPDATE, 10:01 PM: FOX Sports’ Jon Paul Morosi says Indians outfielder Trevor Crowe was pulled from a minor league game Thursday for the purpose of a trade. It’s probably safe to connect the two.

UPDATE, 10:35 PM: Abreu’s agent told Mike DiGiovanna of the Los Angeles Times that he “has not gotten confirmation” that a deal has been agreed to involving his client. This one might take a while.

UPDATE, 10:58 PM: According to Heyman, the Crowe trade that Morosi caught word of earlier is now a “no-go.” It’s not clear whether that means the Abreu trade has also been called off.

UPDATE, 11:27 PM: FOX Sports’ Ken Rosenthal reports that Abreu is only “50-50” to be dealt.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
1 Comment

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.